Table 2.
Results of FB50 staining in studied cohorts
| Variables | No. of cases | +2/+3 FB50, no. (%) | P |
|---|---|---|---|
| Histology | .004 | ||
| ADC | 195 | 55 (28%) | |
| BAC | 18 | 3 (17%) | |
| SCC | 113 | 11 (10%) | |
| LCC | 49 | 5 (10%) | |
| Stage (total of all subtypes) | 375 | 74 | .027 |
| I, II | 325 | 57 (18%) | |
| III, IV | 50 | 17 (34%) | |
| ADC, stage | 195 | 55 | .002 |
| I, II | 180 | 47 (26%) | |
| III, IV | 15 | 8 (53%) | |
| SCC, stage | 113 | 11 | .005 |
| I, II | 95 | 7 (7%) | |
| III, IV | 18 | 4 (22%) | |
| LCC, stage | 49 | 5 | .51 |
| I, II | 32 | 3 (9%) | |
| III, IV | 17 | 2 (12%) |
Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma.